The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H2S-Producing Compound
- 1 January 2015
- book chapter
- review article
- Published by Springer Science and Business Media LLC
- Vol. 230, 325-336
- https://doi.org/10.1007/978-3-319-18144-8_16
Abstract
S-propargyl-cysteine (SPRC), also named as ZYZ-802, is a structural analog of S-allylcysteine (SAC), the most abundant constituent of aged garlic extract. SPRC becomes a derivative of the amino acid cysteine, which contains sulfur atom, by changing allyl group in SAC to propargyl group in SPRC. Another analog of SPRC and SAC is S-propyl cysteine (SPC), which has propyl group instead in its cysteine structure. Drug formulation of SPRC has been investigated in the mixture of extenders, such as lactose, microcrystalline cellulose, and cross-linked povidone, showing good fluidity and scale-up production possibility. Controlled release formulation of SPRC (CR-SPRC) and leonurine-SPRC were invented and shown the decent pharmacological effects in heart failure and hypoxia injury, respectively. The pharmacological effects of SPRC have been shown that cardioprotection and proangiogenesis in several ischemic heart models, neuroprotection in Alzheimer’s disease, proapoptosis in gastric cancer and anti-inflammation in acute pancreatitis. Moreover, CR-SPRC reduced infarct size and recovered partial cardiac function in heart failure rat model. Leonurine-SPRC protected hypoxic neonatal rat ventricular myocytes in much lower dose. Interestingly, since the propagyl group in SPRC has the stronger chemical bond in the cysteine structure than allyl group in SAC and propyl group in SPC, SPRC showed more extensive cardioprotection in ischemic rat hearts model compared to SAC and SPC. The mechanisms of pharmacological effects of SPRC have been unveiled that SPRC reduced Ca2+ accumulation, activated antioxidants, inhibited STAT3, decreased inflammatory cytokines, and elevated p53 and Bax. More pharmacological effects and mechanisms of SPRC will be discovered in atherosclerosis, hypertension, and other diseases.Keywords
This publication has 30 references indexed in Scilit:
- Cardioprotective Effects of a Novel Hydrogen Sulfide Agent–Controlled Release Formulation of S-Propargyl-Cysteine on Heart Failure Rats and Molecular MechanismsPLOS ONE, 2013
- Effects of S-Propargyl-Cysteine (SPRC) in Caerulein-Induced Acute Pancreatitis in MicePLOS ONE, 2012
- H2S Donor, S-Propargyl-Cysteine, Increases CSE in SGC-7901 and Cancer-Induced Mice: Evidence for a Novel Anti-Cancer Effect of Endogenous H2S?PLOS ONE, 2011
- S-Propargyl-cysteine (SPRC) attenuated lipopolysaccharide-induced inflammatory response in H9c2 cells involved in a hydrogen sulfide-dependent mechanismAmino Acids, 2011
- s-Ethyl Cysteine and s-Propyl Cysteine Alleviate β-Amyloid Induced Cytotoxicity in Nerve Growth Factor Differentiated PC12 CellsJournal of Agricultural and Food Chemistry, 2010
- S‐Allyl cysteine, S‐ethyl cysteine and S‐propyl cysteine alleviate oxidative stress‐induced damage within PC12 cellsJournal of the Science of Food and Agriculture, 2008
- Anti-amyloidogenic activity of S-allyl-l-cysteine and its activity to destabilize Alzheimer's β-amyloid fibrils in vitroNeuroscience Letters, 2007
- Hydrogen sulphide and its therapeutic potentialNature Reviews Drug Discovery, 2007
- Protective and Alleviative Effects from 4 Cysteine‐Containing Compounds on Ethanol‐Induced Acute Liver Injury through Suppression of Oxidation and InflammationJournal of Food Science, 2007
- Dietary S-Allyl-L-cysteine Reduces Mortality with Decreased Incidence of Stroke and Behavioral Changes in Stroke-Prone Spontaneously Hypertensive RatsBioscience, Biotechnology, and Biochemistry, 2006